Followers | 8 |
Posts | 1631 |
Boards Moderated | 0 |
Alias Born | 12/09/2000 |
Thursday, November 03, 2005 5:39:24 AM
11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.
Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.
The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.
http://realtimetraders.com/sp/breakingnews.asp?vid=9625264
ENTOURAGE MINING IHUB BOARD, DONT MISS IT. GOTTA BE IN IT TO WIN IT! GOT CMKX?
http://investorshub.advfn.com/boards/board.asp?board_id=4518
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM